Exodus Point Capital Management, LP I Mab Transaction History

Exodus Point Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$4.01 - $12.34 $41,615 - $128,064	10,378 New	10,378 $42,000
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $12.2 Million - $21.4 Million	-254,443 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $4.63 Million - $6.67 Million	104,225 Added 69.38%	254,443 $12.3 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $4.95 Million - $7.08 Million	150,218 New	150,218 $7.08 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.